Bristol-myers Squibb Compnay

Tg Murali Dhar

Ping Chen

Alaric J Dyckman

John V Duncia

Douglas G Batt

Joseph B Santella

John T Hynes

Percy H Carter

Jingwu Duan

Stephen T Wrobleski

Michael G Yang

Scott Hunter Watterson

Robert J Cherney

Daniel S Gardner

Hai-Yun Xiao

John L Gilmore

Yufen Zhao

Satheesh Kesavan Nair

Bin Jiang

Jayakumar Sankara Warrier

Zili Xiao

Qingjie Liu

Edwin J Iwanowicz

Hong Wu

Yeheng Zhu

Lawrence R Marcin

David Marcoux

Lyndon A M Cornelius

Anurag S Srivastava

Qing Shi

Henry H Gu

Lan-Ying Qin

Jianqing Li

Myra Beaudoin Bertrand

Carolyn A Weigelt

Lyndon AM Cornelius

Disclosed are compounds of Formula (I) or a salt thereof, wherein: Ring A is 3- to 6-membered carbocyclic or heterocyclic ring; X is CRor N; Y is &#x2014;(CRR)&#x2014;; Z is &#x2014;(CRR)&#x2014;; and q, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Cyclic compounds useful as modulators of TNF &#x3b1;

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CRor N; W is: (i) &#x2014;(CRR)&#x2014; or (ii) &#x2014;(CRR)x-Y&#x2014;(CRR)y-; and Y, R, R, R, R, R, R, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF&#x3b1;, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Heterocyclic compounds useful as inhibitors of TNF

The present application describes modulators of MIP-1&#x3b1; of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R, R, R, R, Rand R, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators of formula (I) are disclosed. 

Piperidinyl derivatives as modulators of chemokine receptor activity

The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis using the prodrug compounds of the invention are disclosed.

Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity

Compounds having the formula (I),wherein Ris selected from H, OH and NH; Ris selected from &#x2550;O and &#x2550;S; W is &#x2014;C(&#x2550;O)&#x2014;, &#x2014;S(&#x2550;O)&#x2014;, or &#x2014;S(O)&#x2014;; or W may be &#x2014;CH&#x2014; if X is &#x2014;C(&#x2550;O)&#x2014;; X is selected from &#x2014;CH&#x2014;, &#x2014;N(R)&#x2014;, and &#x2014;O&#x2014;, except that when W is &#x2014;CH&#x2014;, X is &#x2014;C(&#x2550;O)&#x2014;; Y is a bond or &#x2014;C(R)(R)&#x2014;; Q is a linker; Z is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; and X, X, X, X, X, X, X, X, X, Xand Xare selected such a tricyclic heteroaryl ring system is formed as further defined in the specification.

Heterocyclic acridone inhibitors of IMPDH enzyme

Growing community of inventors

Newtown, PA, United States of America

Tg Murali Dhar